Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia

David J. Kuter(Harvard University), Dietmar Berger(Amgen (United States)), Dominik Selleslag(National Institutes of Health), Mathias Rummel(Universitätsklinikum Gießen und Marburg), Ingrid Pabinger(Medical University of Vienna), Xuena Wang(Tianjin University of Traditional Chinese Medicine), B. Gail Macik(University of Virginia), Ralph V. Boccia(Center for Cancer and Blood Disorders), Beng H. Chong(The University of Texas Southwestern Medical Center), Francesco Rodeghiero(Ospedale San Bortolo)
New England Journal of Medicine
November 10, 2010
10.1056/nejmoa1002625
Cited by 425

Related Papers

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
|Blood|2008|2.6k
Defining Opportunistic Invasive Fungal Infections in Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: An International Consensus
|Clinical Infectious Diseases|2002|2.3k
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
|The Lancet|2013|1.5k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Updated international consensus report on the investigation and management of primary immune thrombocytopenia
|Blood Advances|2019|1.1k